Page 142 - 2019_02-Haematologica-web

S-K. Leivonen et al. Melanoma-intrinsic beta-catenin signalling
prevents anti-tumour immunity. Nature.
2015;523(7559):231-235.
25. Sweis RF, Spranger S, Bao R, et al.
Molecular Drivers of the Non-T-cell- Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016;4(7):563-568.
26. Pollari M, Bruck O, Pellinen T, et al. PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict sur- vival in primary testicular lymphoma. Haematologica. 2018;103(11):1908-1914.
27. Goodman A, Patel SP, Kurzrock R. PD-1- PD-L1 immune-checkpoint blockade in B- cell lymphomas. Nat Rev Clin Onc. 2017;14(4):203-220.
28. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. New Engl J Med. 2015;372(26):2521-2532.
29. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined
Nivolumab and Ipilimumab in Advanced Melanoma. New Engl J Med. 2017; 377(14):1345-1356.
30. Pereira C, Gimenez-Xavier P, Pros E, et al. Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition. Clin Cancer Res. 2017;23(12):3203-3213.
31. Allegra A, Russo S, Gerace D, et al. Vaccination strategies in lymphoprolifera- tive disorders: Failures and successes. Leuk Res. 2015;39(10):1006-1019.
32. Brudno JN, Kochenderfer JN. Chimeric anti- gen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31-46.
33. Goebeler ME, Knop S, Viardot A, et al. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non- Hodgkin Lymphoma: Final Results From a Phase I Study. J Clin Oncol. 2016;34(10): 1104-1111.
34. Pishko A, Nasta SD. The role of novel
immunotherapies in non-Hodgkin lym-
phoma. Transl Cancer Res. 2017;6(1):93-103. 35. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New Engl J Med.
2017;377(26):2531-2544.
36. Viardot A, Goebeler ME, Hess G, et al.
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lym- phoma. Blood. 2016;127(11):1410-1416.
37. Cycon KA, Mulvaney K, Rimsza LM, Persky D, Murphy SP. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology. 2013;140(2):259- 272.
38. Jiang Y, Ortega-Molina A, Geng H, et al. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discov. 2017;7(1):38- 53.
346
haematologica | 2019; 104(2)